Eaton Vance Worldwide Health Sciences Fund

Scorecard
3 / 5 Stars
Lipper
2 2 5 1 2
Zacks Investment Research
2 (Buy)
Standard & Poor's
3 / 5 Stars
TheStreet.com
A+ (Buy)

U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Eaton Vance funds

See full Health rankings

See more fund rankings

Performance

The fund has returned 50.15 percent over the past year, 23.72 percent over the past three years, 21.46 percent over the past five years, and 9.72 percent over the past decade.

Trailing Returns Updated 02.28.2014
Year to date 12.6%
1 Year 50.2%
3 Years (Annualized) 23.7%
5 Years (Annualized) 21.5%
10 Years (Annualized) 9.7%

See more ERHSX performance

Summary

The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It concentrates (that is, invests at least 25% of its assets) its investments in medical research and the health care industry. The fund may invest up to 5% of its total assets in royalty bonds.

Fees

Fees are Low compared to funds in the same category.
Eaton Vance Worldwide Health Sciences Fund has an expense ratio of 1.64 percent.

See more ERHSX fees

Risk

Risk is Average compared to funds in the same category according to Morningstar.

See more ERHSX risk